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Abstract: Introduction: Minimally invasive surgery (MIS) in the surgical management of esophageal cancer is now 
accepted as a valid technique. The aim of this study is to show our initial experience with this approach. 
Material and Methods: Observational study using data collected prospectively from a database, which includes 23 
patients operated by MIS. Esophageal dissection was performed by videothoracoscopy, followed by laparotomy or 
laparoscopy. An Akiyama gastroplasty was made up, and pulled up through the posterior mediastinum and an side-to-
side esophagogastric cervical anastomosis was then performed. 
Results: Most of the patients (19) were male and the average age was 63.3 years. Most tumors were located underneath 
the carina. 17 were adenocarcinomas and 6 squamous cell type. 19 patients received neoadjuvant therapy. The average 
operating time was 377.5 minutes and in 5 patients it was necessary to make a thoracotomy to finish the esophageal 
dissection. An average of 18 lymph node were removed and the most frequent pathological stage was the IIA. The 
morbidity was 47.8%, 5 patients with respiratory complications and 7 patients presenting a anastomosis leakage or 
fistula. 3 patients died postoperatively. The average follow-up was 23.5 months and the estimated 5-year overall survival 
was 61.8%. 
Conclusion: This study confirms previous reports about MIS which seems to be a valid technique if made by experienced 
teams. Our results support a satisfactory oncological outcome and a low rate of respiratory complications. 
Keywords: Minimally invasive surgery, Thoracoscopy, Esophageal cancer, Laparoscopy, Outcome, Complications. 
INTRODUCTION 
Minimally invasive surgery (MIS) in esophageal 
cancer is a form of surgical approach that has been 
increasing over the last decade [1-7]. However, the 
high morbidity and mortality of this procedure [1-3, 8-
13] and the complexities of the learning curve [1, 14, 
15] have contributed to its underdevelopment. This 
procedure can be divided into two forms: the “non-total” 
minimally invasive surgery which includes 
thoracoscopy or laparoscopy, but not both, and the 
“total” minimally invasive surgery which includes 
thoracoscopy and laparoscopy in the same patient [2, 
4, 8, 14,16-18]. The question about which procedure is 
better has been widely discussed without getting into 
specific rules for handling. It can be only concluded that 
the most important arguments are the preference and 
the experience of the surgical team, and a high volume 
of patients referenced to a center [5, 9, 10, 19-22]. 
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Often it is not easy both match. Many studies support 
better outcomes for the MIS, describing a decreased in 
the respiratory complications rate [6, 8, 16, 19, 20, 23-
28], a shorter recovery time, a shorter stay in the 
critical care unit (ICU) and an earlier hospital discharge 
[6, 8, 11, 19-21, 23]. On the other hand MIS has not 
been shown to have an impact on operative mortality or 
survival rates [3, 7, 8, 17, 19, 21, 23, 24, 29, 30]. 
Currently this approach is accepted as a valid 
technique that would not compromise the oncological 
results [3, 4, 29, 31], and it is especially indicated in the 
initial stages of the disease. The aim of this study is to 
show the experience in the surgical management of the 
esophageal cancer treated by minimally invasive 
surgery in our center. 
MATERIAL AND METHODS 
Patient’s Selection 
This is an observational study of patients diagnosed 
of esophageal cancer collected prospectively from a 
database since 2002 in our unit of gastro esophageal 
surgery. Of the 139 patients diagnosed of esophageal 
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cancer, 93 underwent surgery with curative intent. 
Esophagectomy using minimally invasive surgery 
began in 2007 in our center, and since then 23 patients 
have been operated by this approach, which are the 
object of this study. Patients flow diagram is shown in 
Figure 1. It includes patients diagnosed of aden- 
ocarcinoma or squamous cell carcinoma of the 
esophagus and those Siewert type I located in the 
gastro esophageal junction. Patients with metastasis, 
tumor located in the cervical esophagus, ASA greater 
than 3 and those whose respiratory function tests 
showed a FEV1 <70% and / or FEV1 / FVC <70% were 
excluded. 
Diagnosis and Staging Studies 
Diagnosis was always performed with endoscopy 
and biopsy. The staging study was performed using 
computed tomography (CT-scan). Endoscopic 
ultrasonography was used in those cases where the 
CT-scan could not discriminate between patients with 
local disease (T1 or T2, N0) of those with locoregional 
disease (T3 / T4 or N+), in order to define the 
candidates for neoadjuvant therapy. PET-scan and/or 
MRI was only performed in cases of doubt of 
metastatic disease and / or distant lymph nodes 
involvement. Tumor location was defined 
endoscopically as supracarinal, infracarinal or located 
in the esophagogastric junction (Siewert I). A 
bronchoscopy was performed in all patients with 
tumors classified as supracarinal or infracarinal. 
Adjuvant Therapy 
Patients staged as T3 and/or N+ were treated with 
neoadjuvant therapy: chemoradiation (45 Gy + 
FEC(Fluorouracil (5FU), epirubicin and 
cyclophosphamide) in patients with esophageal 
squamous cell carcinoma and perioperative 
chemotherapy (mostly "XELOX" Oxaliplatin 130 mg / 
m2 / day for 3 weeks + Capecitabine 2000 mg / m2 / 
day for 15 days, three preoperative cycles) in patients 
diagnosed of adenocarcinoma. Response was 
assessed using the CT-scan. PET was only used in 
those cases where there was a doubt of the presence 
of metastasis and/or distant lymph nodes involvement 
in the CT-scan in order to identify patients with a 
progression of the disease. After 4 weeks of the 
completion of chemotherapy in cases of 
adenocarcinoma, and 6 weeks after the completion of 
radio chemotherapy in cases of squamous cell 
carcinoma, patients underwent esophagectomy using a 
minimally invasive approach. 
Surgery 
Surgery was performed using a selective bronchial 
intubation to exclude the right lung during the 
thoracoscopy approach. An epidural catheter for 
 
Figure 1: Flow chart of patients diagnosed of esophageal cancer. 
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analgesia was placed in all patients. The minimally 
invasive techniques used were a combination of 
videothoracoscopy (VTC) and laparoscopy, with an 
intrathoracic esophagogastric anastomosis in cases of 
tumors located in the lower esophagus, or a cervical 
anastomosis in those tumors located in the middle and 
upper thoracic esophagus. For the VTC approach, the 
patient is placed in the left lateral or prone position, and 
3 ports are placed in the infrascapular region, in the 
anterior axillary line on the 5th right intercostal space 
and in the mid-axillary line on the 8th intercostal space. 
An additional fourth port was used if needed. 
Conversion was considered in cases where dissection 
of the esophagus via VTC could not be completed and 
a formal thoracotomy was required. For the abdominal 
approach, the patient is placed in the supine position 
and five ports (1 in the supraumbilical midline, 2 in the 
right upper quadrant, and 2 in the left upper quadrant) 
were placed. An Akiyama tubular gastroplasty was 
performed and conducted through the posterior 
mediastinal route. An esophagogastric side-to-side 
mechanical anastomosis was then performed. If the 
patient has no stomach or has a previous stomach 
surgery, the transverse colon was used. 
Postoperative Period 
During the first postoperative 24 hours, the patient 
remains in the intensive care unit (ICU) and depending 
on the clinical conditions is transferred to the surgical 
ward. Operative mortality and morbidity were defined 
as those occurred within 30 days after surgery. 
Patients with anastomotic leakage were classified as 
dehiscence (associated sepsis that can not be 
controlled by drains) or fistula (filtration that can be 
controlled by a drain placement or by puncturing). 
Follow-Up 
Follow-up was performed through clinical evaluation 
and CT-scan every six months for two years and then 
annually for five years. Gastroscopy was only 
performed in those cases where a local recurrence was 
suspected.  
The following clinical variables were collected: age, 
sex, clinical features (presence of dysphagia and 
preoperative hemoglobin, ASA), medical history 
(smoking, alcoholism, gastroesophageal reflux disease 
(GERD), Barrett's disease), parameters of nutritional 
status (albumin , prealbumin, BMI), tumor location, 
response to neoadjuvant therapy , type of surgery, 
transfusion, operative time, conversion rate and 
causes, intraoperative complications, reoperations, 30-
days related operative morbidity and mortality, ICU and 
hospital stay, pathological tumor characteristics , tumor 
stage, disease-free survival and overall survival. The 
6th edition of the TNM, 2002 was used for staging. For 
the statistical analysis, the Kaplan-Meier test and t-test 
were used. 
RESULTS 
Of the 23 patients operated by MIS, 19 were male 
and 4 were female. The mean age was 63.3 years. 
Clinical features, medical history and nutritional status 
are shown in Table 1. There were 2 patients with 
previous history of neoplasia; one operated of a 
squamous cell cancer of the mouth, and one with a 
sigmoid colon cancer. 8 (35%) patients underwent EUS 
for staging purpose. The tumors location were: 4 (17%) 
supracarinal, 11 (48%) infracarinal and 8 (35%) at the 
esophagogastric junction. 17 (74%) were 
adenocarcinomas and 6 (26%) squamous cell type. 
Table 1: Clinical Features, History and Nutritional 
Status 
 N % 
Clinical features   
Presenting dysphagia 21 91 









Haemoglobin (11 mg/dl) 3 13 
Medical History   
Smoking 16 70 
Alcoholism 8 35 
GORD 5 22 
Barrett 6 26 
Nutritional markers   
Albumin (3,5g/dl)  3 13 
Prealbumin (20 mg/dl) 3 13 
BMI (<20 Kg/mt2) 2 9 
 
19 (83%) patients received neoadjuvant therapy . Of 
these, 4 (21%) received radiotherapy and 
chemotherapy and 15 (79%) chemotherapy alone. The 
4 patients who received radiation and chemotherapy 
presented a partial response to treatment. Of those 
receiving chemotherapy alone, 1 (7%), 12 (80%) and 2 
(13%) presented a complete, a partial response and no 
response respectively. 
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All patients underwent VTC initially. VTC + VLC was 
performed in 5 (22%) patients and VTC + laparotomy in 
18 (78%) patients. Conversion into thoracotomy or 
minithoracotomy occurred in 5 patients (22%); 4 for 
technical difficulties due to an inflammatory reaction 
and/or tumor invading surrounding structures, and 1 for 
bleeding that could not be controlled via VTC. The 
average operating time was 377.5 minutes (range, 225-
590 minutes). The average time in the VTC + 
laparotomy group was 350 minutes and 469 minutes in 
the VTC + VLC group. 22 (96%) patients underwent 
subtotal resection + gastric lesser curvature 
esophagectomy and cervical anastomosis, and 1 (4%) 
patient had a partial esophagectomy + lesser curvature 
gastric resection with intrathoracic anastomosis due to 
a previous cervical cancer surgery. In 22 (96%) 
patients, an Akiyama's tubular gastroplasty were 
performed, and in 1 (4%) patient an isoperistaltic 
transverse colon loop was used because a previous 
gastrectomy for benign disease. During surgery, 10 
(43%) patients were transfused (8 patients received 2 
packets of red blood cells, and 2 patients received 3 
packets of red blood cell). None of the 23 patients 
presented serious operative complications during 
surgery. The median stay in the ICU was 1 day (range 
1-90), and median hospital stay was 15 days (range 
11-98). 11 (48%) patients presented postoperative 
morbidity and 3 (13%) patients died. Comparing groups 
(VTC+ LAP vs VTC + VLC), morbidity was higher in the 
first group, 56% and 40% respectively. Table 2 shows 
the operative morbidity and mortality of the serie. No 
patients presented with recurrent laryngeal nerve 
injury, postoperative bleeding or chylothorax. Of the 
seven patients presenting an anastomotic leakage, 
three were handled succesfully by conservative 
management; two were sealed off with sealant glue by 
endoscopy (one died), and one by suturing and 
placement of drainages. One patient presented a 
necrosis of the coloplasty which was resected and a 
jejunostomy performed. The mortality was associated 
with sepsis secondary to anastomotic leakage. 
R0 surgery was performed in 22 (96%) patients and 
only 1 (4%) patient presented the margin affected by 
tumor, which corresponded to a supracarinal pT4 
squamous cancer located at 25 cm distal from the 
dental arch. The mean of lymph nodes resected was 
18; 6.9 in the mediastinal area and 11.1 in the 
abdomen. Pathological staging of the serie is as follow: 
4 (17%) stage I, 10 (43%) Stage II A, 4 (17%) Stage II 
B, 4 (17%) stage III, and 1 (4%) Stage IV. The average 
follow-up was 23.5 months. 7 patients (35%) presented 
a recurrence. Table 3 shows the evolution of patients 







Air Leakage Abdominal Wound 
Dehiscence 
Management Mortality 
1 ARDS YES Leakage   Endoscopic sealing YES 
2  YES 
Coloplasty necrosis 
 
  Coloplasty resection + 
jejunostomy 
YES 
3  YES Leakage 
Bronchial 
fistula 




ARDS + Pleural 
effusion YES Leakage 
   Drainage placement + 
endoscopic stent 
NO 
5  NO Fístula   Medical NO 
6  NO Fístula   Medical NO 
7 
Pneumonia + 
Pulmonar abscess NO Fístula 
  Medical NO 
8 
Pneumonia + 
ARDS YES  
  Medical NO 
9 Pneumonia NO    Medical NO 
10  NO   YES Surgery NO 
11  NO  Air leakage  Drainage placement NO 
Total 







* ARDS: Adult Respiratory Distress Syndrome. 
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presenting the recurrence. Figure 2 and 3 show the 
overall survival and the disease-free survival of the 
serie respectively. The estimated 5-year overall 







Current treatment of esophageal cancer must be 
multidisciplinary. Much progresses have been made in 
the field of adjuvant therapy for improving survival. But 
surgery remains the cornerstone in the curative 
treatment of this disease, although the percentage of 
patients eligible for surgery with curative intent remains 
being low. This has made that the team experience is 
related to a small number of patients, with the 
consequent delay in the application of the new 
techniques. On the other hand, it is considered a very 
aggressive surgery, often in elderly patients who 
usually present comorbidities. This makes that surgical 
outcome results poor, with high morbidity and mortality 
rates. It has been reported that the main causes of 
morbidity and mortality are secondary to the 
development of respiratory complications and to 
dehiscence of the anastomosis. So one of the goals of 
the treatment has focused on improving these aspects. 
Although MIS has failed to show an impact on reducing 
the mortality, it has a role reducing the pulmonary 
complications rates. Respiratory complications rate 
reported for open surgery ranges from 30 to 38.7% 
while MIS ranges from 6,7 to 20% [18,24,25] , which 
results quite similar to those described by us. 
Our experience in the esophageal dissection went 
smoothly, without serious complications, although two 
patients presented a persistent air leak in the 
immediate postoperative period. The conversion rate to 
minithoracotomy was 22%, which may be attributable 
to the learning curve, where large tumors should not be 
candidates for MIS, especially in early stages of the 
learning curve. We believe it is valid to apply mixed 
techniques (laparotomy/thoracoscopy or 
thoracotomy/laparoscopy). Our experience in totally 
Table 3: Patients Presenting Recurrence 
Patient 
No 
Recurrence Location Disease-free 
Survival 
Management Actual Status Survival Stage 
(yp TNM) 
1 Lymph node recurrence 7 Palliative chemotherapy Dead 22 II A 
2 Mediastinum + Lung 11 Palliative care Dead 17 II B 
3 Bone metastasis 7 Palliative care Dead 15 II B 
4 Peritoneal 14 Palliative care Dead 14 II B 
5 Liver + peritoneal 6 Palliative care Live 8 III 
6 Pleural 18 Palliative chemotherapy Live 30 II B 
7 Lung 22 Intent curative Lobectomy  
Disease-free 
live 
35 II A 
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minimally invasive techniques was favorable, except for 
an increase in the operating time which has been 
already described by other authors. Oncologic 
outcomes are also acceptable and comparable to high-
volume series, 96% of R0 resections, 15 or more lymph 
nodes removed and quite similar survival rates. 
Concerning to the dissection of the esophagus, our 
experience resulted quite similar to those described by 
other authors which advocate that VTC could facilitate 
the esophageal dissection compare to the open 
approach.  
VTC must be performed by experienced teams in 
the classical open approach since it has an important 
impact on the surgical outcome. Our dehiscence and 
mortality rate are slightly higher according to the latest 
reports [4, 9, 24, 26, 33, 34], however we believe this is 
not attributable to the minimally invasive approach, 
considering that the most complicated patients were 
approached by laparotomy. The VTC approach 
facilitates the dissection of the esophagus especially in 
smaller tumors, with a similar oncological outcome and 
reducing the aggression of a thoracotomy. This 
involves the consequent decrease of pulmonary 
complications. 
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